ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

INP Inspicio

226.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Inspicio LSE:INP London Ordinary Share GB00B07BZ776 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 226.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Inspicio Share Discussion Threads

Showing 126 to 148 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
08/5/2007
11:25
Honiton - you can add Velosi [VELO] to the list; it's certainly exceeding my expectations.
As for INP, I intend holding for some time if all goes to their plan.

More news from Inspectorate:

On the 13th April 2007, Inspectorate America Corporation signed a contract with SENASA (National Service for Animal Health) of Costa Rica to carry out the analysis of all food exportation from Costa Rica to the European Union.

The European Union has very stringent requirements on food safety before allowing food products to enter its borders. Each exporting country needs to prove to the European Union that they meet these standards and that they are carrying out frequent control of their food exports. The EU demands that an accredited laboratory (ISO17025) carries out these analyses and that the laboratory has the necessary technology and validated methods. Currently in Costa Rica, no such lab exists, and therefore the Costa Rica Government approached Inspectorate to provide the solution. The Costa Rica Government has named Inspectorate del Ecuador's ISO17025 lab in Guayaquil as their official food safety analysis laboratory.

Sampling of product will take place (starting immediately) in Costa Rica and samples will be sent to Ecuador on a regular basis for analysis. Inspectorate del Ecuador already carries out a wide range of control of food products for Ecuadorian, Panamanian, Colombian, Peruvian and Venezuelan clients.

This project is being managed by Inspectorate Panama, with the analysis being carried out in Ecuador.

jonwig
07/5/2007
15:10
Jonwig

good spotting. At the moment the market is hot for any service companies e.g. RTR, INP, SWG, WSP, WHY.

Don't see any reason to sell INP yet.

honiton
07/5/2007
14:59
This could be big enough for a RNS from INP tomorrow:

TORONTO, ONTARIO -- (MARKET WIRE) -- May 07, 2007 -- Eurocontrol Technics Inc. (TSX VENTURE: EUO), a Canadian public company specializing in the acquisition, development and commercialization of innovative authentication and verification technologies, through its wholly owned subsidiary Global Fluids International S.A. (GFI), today announced the signing of a comprehensive worldwide Master Memorandum of Understanding (MMOU) with Inspectorate International Limited for the global deployment of GFI's hydrocarbon marking technology Petromark™.

More:

jonwig
25/4/2007
05:24
once again nothing negative to suggest selling INP.
honiton
24/4/2007
09:22
A Questor article today on ITRK might be relevant; prospective P/E of 18.5 and possible takeover by SGS (Switzerland):
jonwig
04/4/2007
19:34
thank goodness for the rise. just about to hit my stoplos of -15% from all time high....
honiton
02/4/2007
12:55
Wiganer - quite so. However, I'm not one to cover my tracks by editing posts!

On a longer view, the strategy seems logical, though.

jonwig
02/4/2007
12:00
I'm not sure your prediction of a takeover of COT looks especially likely right now...


Inspicio Disposal


RNS Number:2270U
Inspicio plc
02 April 2007


Press Release, April 2 2007

Inspicio plc

("Inspicio" or the "Company")

Disposal of investment in Concateno plc ("Concateno")

Inspicio plc, the UK and international inspection and testing company, announces
that it has disposed of its entire holding of 1,397,059 shares in Concateno at a
price of 145 pence per share. The net proceeds of #2.01 million, realising a
profit of approximately #0.8 million, will be used to reduce net debt.


Inspicio's disposal was made at the time of Concateno's placing of 11.03 million
shares in connection with its acquisition of Euromed Limited, which was
announced on 30 March 2007. This is Concateno's fourth acquisition and placing
to date.


The trading agreement between Inspicio and Concateno which allows Medscreen,
Concateno's principal operating testing business, to grow through access to
Inspectorate's global infrastructure and provides a number of potential
additional revenue streams for Inspicio, remains in place and is not affected by
the disposal.

Mark Silver, Chief Executive of Inspicio, said:

"Inspicio's holding in Concateno has been significantly diluted by Concateno's
recent equity raisings and no longer represents an effective strategic
investment for us. We therefore decided to realise the profit and use the
proceeds to provide more financial flexibility. The trading agreement with
Concateno remains in place to enhance the range of Inspicio's global inspection
and testing offering and we remain confident that working together will generate
revenue benefits to our core business."


- Ends -

For further enquiries, please contact:

Richard McBride, Inspicio 020 7248 0802

Chris Blundell, Brunswick 020 7404 5959


About Inspicio

Inspicio was admitted to AIM on 29 April 2005 as a newly incorporated company,
established to acquire and manage organisations in the testing, inspection and
performance conformity markets, both in the UK and internationally. The group
has over 5,000 employees operating in almost 130 countries and a framework for
continued growth.


Inspicio's strategy is focused on growth. It intends to use its global
infrastructure to drive international expansion and its mission is to become a
significant global player in the testing, inspection and performance conformity
market.


Inspicio initially invested in a 5 per cent stake in Concateno in November 2006.

More information is available at www.inspicioplc.com


About Concateno


Concateno was admitted to trading on AIM on 7 April 2005 as an investing
company. On October 27 2006, it announced the acquisition the entire issued
share capital of Medscreen Limited, a global provider of drug and alcohol
testing services, providing management solutions for the problems that drugs and
alcohol bring to the working environment, for a purchase price of #30 million.
The acquisition of Euromed Limited is its third subsequent acquisition.


Inspicio subscribed for 1,397,059 new ordinary shares in Concateno at a price of
85 pence per share on the acquisition of Medscreen Limited, but has subscribed
for no further shares in its subsequent acquisitions.


Concateno is chaired by Keith Tozzi, the Chairman of Inspicio. Keith continues
to chair both companies, using his considerable knowledge of the inspection and
testing industry to deliver value for both groups of shareholders.






This information is provided by RNS
The company news service from the London Stock Exchange

END
DISITMTTMMIMBLR

wiganer
02/4/2007
11:23
Hi, H.

I added last week when the share price dropped after the results - trouble is, it dropped some more. No worry, though, as I intend holding this for several years - all being well.

I see Concateno [COT] has just announced a significant contract win to test police officers for drugs, etc.
Since one of the key drivers for INP is acquisition in a fragmented market, I feel a takeover for COT is only a matter of time. That could well be a 'nil-premium' offer, but in the longer term, should benefit.

jonwig
31/3/2007
17:24
thanks jonwig.

recent weakness could be a time to buy as the fundamentals aint changed.

honiton
31/3/2007
11:17
Analyst presentation given on the day of the results:
jonwig
24/3/2007
14:27
Yorkshire Post, mostly Eclipse Scientific:

Food scares bring benefit to Eclipse

By Greg Wright Deputy Business Editor
FOOD scares and red tape are speeding up the global expansion of a business headed by a Yorkshire entrepreneur whose career began with a Prince's Trust Grant.
Food testing business Eclipse Scientific Group's strong performance helped its new owner, Inspicio, move into profit last year.

Eclipse's managing director Julie Dedman said the company was set to grow internationally, as scares surrounding avian flu and salmonella force regulators to impose tougher tests on food quality.

Yesterday inspection and testing business Inspicio revealed that it posted a pre-tax profit of £500,000 in 2006, compared to a loss of £4.5m the year before. Full year group turnover soared from £26.2m to £161.9m

Last August, Clearbrook Capital Partners, the private equity investment firm established by female banker Robin Saunders in 2004, sold Eclipse for £47m to Inspicio, which is listed on the Alternative Investment Market (AIM).

Clearbrook, together with RIT Capital Partners and Lord Rothschild's family interests, had backed a management buyout by Ms Dedman, Eclipse's chief executive, in 2004 and funded an expansion programme.

Ms Dedman, who has been in the food testing industry for more than 20 years, stayed on as Eclipse's managing director after last year's sale. At the age of 21, Ms Dedman started West Riding Laboratory Services in 1985 with a £1,000 grant from the Prince's Trust. She sold the business to Mowlem in 1999. She joined Eclipse in 2002 as chief executive and led a management buyout of the firm from Swan Group in 2004.

Yesterday it was revealed that Cambridgeshire-based Eclipse, which employs 30 of its 370 staff in Mirfield, West Yorkshire, had generated sales of £7.7m and operating profit of £1.7m between August 11 and December 31 2006.

Ms Dedman, who is from Mirfield, said: "Eclipse has made a great contribution to profit. We know how to make brass in Yorkshire. We are looking at further expansion within
the general food testing market.
"My career has been an incredible journey. Over the last five years, since I started working with Robin (Saunders) the momentum has really picked up. She's been a tremendous inspiration."

Mark Silver, Inspicio's chief executive, said the US market was an obvious area for Eclipse's expansion, along with Europe and the Far East.

Food safety has never been more topical. A salmonella scare in June last year forced Cadbury to take more than a million chocolate bars off the shelves of British stores. In February, 159,000 turkeys at a Bernard Matthews turkey farm in Suffolk were slaughtered following a bird flu outbreak.

Mr Silver said food scares had helped Inspicio's growth.
He added: "We get a little boom in the business – everybody tests like mad but there is also more legislation and more outsourcing of operations.

"We see the food testing market growing over the next three to five years by 20 per cent per annum."

Apart from food testing, Eclipse provides water and pharmaceutical testing services and also has a laboratory supply company. Eclipse has acquired two other food testing businesses since August – Promar and Envirolab – for a total cost of £400,000.

jonwig
23/3/2007
15:21
And Citywire;

Small may have been beautiful towards the end of the 20th century, but in these days of globalisation, increased regulation, high barriers to entry and growing world trade, size has become increasingly important.

In some areas you need to be big to compete, and one of these is in the testing of oil and petroleum in terms of quantity and quality. If results are to mean anything, tests need doing in the same way by the same company when oil is piped into a tanker and when it's pumped out at the other end of its voyage.

The highly fragmented nature of the international testing market is why AIM-listed international inspection and testing group Inspicio (INP) was formed nearly two years ago, explains chief executive Mark Silver.

Group turnover for the 12 months to 31 December was £161.9 million against £26.2 million in 2005. The comparative figures for 2005 include head office costs from the date of incorporation in April and the trading results of the petroleum specialists Inspectorate from its acquisition in October 2005.

Close to half the turnover came from America. Although Inspicio is involved with metal and mineral testing, where high gold and other precious metal prices increased analysis requirements, the business was driven by oil and petroleum testing.

South America was more diversified with new laboratories in Venezuela and water testing in Argentina. Europe, the Middle East and Africa accounted for £52.4 million or 41.5% of sales while Asia chipped in with £11.3 million, or 9.1%.

Earnings before exceptional items, amortisation, interest and tax were £7.6 million compared to a loss of £500,000 in the 38 weeks to 31 December 2005. Group profit before interest and tax was £3.2 million against of loss last time of £4.3 million, in-line with expectations. There is no dividend.

Market consensus was for pre-tax profit of £5.42 million and earnings per share of 3.92p.

The shares fell 5.25p to 165p giving the group a stock market value of £146.5 million. The company has seen 70% growth and its shares have outperformed the market by 27% over the last year.

Investors in Inspicio include Framlington's UK Smaller Co's fund and F&C's open ended UK Smaller Co's Fund. Cycladic, JO Hambro and SG Asset Management also have stakes.

Broker Bridgewell kept its buy recommendation and said it would review its 210p target price. It noted the results were in line with its forecasts and reflect excellent performance across its divisions, but that forecast higher interest charges would lower forecasts by about 5%.

Altium also maintained its buy recommendation with a 200p price target.

'Encouragingly, the Inspectorate turnaround is proceeding to plan and the wider
market outlook remains positive,' the broker wrote in a note to investors.

With turnover of £126.1 million, the Inspectorate side of the Inspicio group is by far the biggest. Operating profit before exceptional items was £5.2 million compared to a loss of £600,000 in the 12 months to 31 December 2005 on a pro forma basis.

The balance of turnover came from the Environmental Services Group with £28.1 million in the eight months since acquisition and the Eclipse Scientific Group with £7.7 million with 20 weeks.

The Environmental Services Group, bought from Carillion for £16 million, specialises in the testing of ground used for development, anything from a house to a football stadium. It includes businesses in the soil, environmental and building testing sector and provides laboratory-based tests and consultancy services.

On 11 August 2006, Inspicio acquired the Eclipse Scientific Group for £47 million. It concentrates on food testing and is a market leader in both the UK and Ireland.

There were a number of smaller acquisitions costing around £4.9 million which added £1.1 million to turnover. These included a majority stake in Inspectorate's Libyan agent, while the minority interest in Hungary was acquired outright. Inspectorate also bought an agent in Portugal and expanded its metals and minerals services in Australia by taking over the Renton Laboratory.

Group margins were 4.2% against a pro forma loss last time of 0.6%. The turnaround was achieved by reducing costs, taking on a larger proportion of higher margin testing work and higher prices, explains Silver.

Margins are expected to reach 8% in the second half of this year. Analysts were forecasting profit before tax of £13.2 million for 2007, but this is expected to increase after the analysts' meeting later today.

jonwig
23/3/2007
13:02
Inspicio INP Altium Capital Buy 166.00p 200.00p - Reiteration
23-Mar-07 Inspicio INP Daniel Stewart Hold 166.00p 190.00p - Reiteration

cambium
23/3/2007
07:56
a bit up in the air.

so long as deliverying on target then should be ok.

they appear to be.

no prediction.

honiton
23/3/2007
07:26
T/O £161.9m. (Median Forecast £158.6m)

Profit before exceptional items, interest and tax £4.7m (Median Forecast £5.8m)

At the long run normalised tax rate of 35 per cent, the EPS was 4.4p. (Median Forecast 4.5p).

Too many factors in the form of exceptionals to make much of the figures at 7:00am, but the 'director speak' is very positive.

jonwig
22/3/2007
07:21
Honiton - well, INP have already said they are 'in line'.
Obviously they could make some very bullish forward-looking statements, but I don't really think that's their style.

So who knows?
I've a price in mind for adding to my holding, a bit below the current.

I suppose you could do a bit of both - half now, half after the figures.

jonwig
22/3/2007
07:07
could be.

had a hairy day yesterday with Civica. Sold on nerves!!!

jonwig: what do you think? should I buy some more INP today or wait until tomorrow??

honiton
22/3/2007
07:01
End of tax year, even?
Some people may take some profits now if within the allowance.

jonwig
21/3/2007
21:09
is this pre results jitters?
honiton
21/3/2007
15:35
J O Hambro Capital Management holding increased from 5,540,000 (6.01%) to 6,436,806 (7.29%).
jonwig
19/3/2007
12:14
results friday
honiton
06/3/2007
17:19
Absoluelty, recent weakness points to opportunity to buy.
honiton
Chat Pages: 10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock